



Rescriptor[®] (delavirdine) – Product discontinuation

- On June 26, 2019, the [FDA announced](#) the discontinuation of ViiV Healthcare's [Rescriptor \(delavirdine\)](#) 200 mg tablets.
 - The discontinuation was due to business reasons and is not due to any safety, efficacy or quality issues.
 - The anticipated final date for availability to patients is January 2020.
- Rescriptor is approved for the treatment of human immunodeficiency-1 infection in combination with at least 2 other active antiretroviral agents when therapy is warranted.



OptumRx[®] specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum[®] company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum[®] trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews[®] is published by the OptumRx Clinical Services Department.

©2019 Optum, Inc. All rights reserved.